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A B S T R A C T
Transactive response DNA-binding protein of 43 kDa (TDP-43) functions as a heterogeneous nuclear ribonu-
cleoprotein and is the major pathological protein in frontotemporal lobar degeneration (FTLD) and amyotrophic
lateral sclerosis/motor neuron disease (ALS/MND). TDP-43 pathology may also be present as a comorbidity in
approximately 20–50% of sporadic Alzheimer’s disease cases. In a mouse model of MND, full-length TDP-43
increases association with the mitochondria and blocking the TDP-43/mitochondria interaction ameliorates
motor dysfunction. Utilizing a proteomics screen, several mitochondrial TDP-43-interacting partners were
identified, including voltage-gated anion channel 1 (VDAC1) and prohibitin 2 (PHB2), a crucial mitophagy
receptor. Overexpression of TDP-43 led to an increase in PHB2 whereas TDP-43 knockdown reduced PHB2
expression in cells treated with carbonyl cyanide m-chlorophenylhydrazone (CCCP), an inducer of mitophagy.
These results suggest that TDP-43 expression contributes to metabolism and mitochondrial function however we
show no change in bioenergetics when TDP-43 is overexpressed and knocked down in HEK293T cells.
Furthermore, the fusion protein mitofusin 2 (MFN2) interacts in complex with TDP-43 and selective expression
of human TDP-43 in the hippocampus and cortex induced an age-dependent change in Mfn2 expression.
Mitochondria morphology is altered in 9-month-old mice selectively expressing TDP-43 in an APP/PS1 back-
ground compared with APP/PS1 littermates. We further confirmed TDP-43 localization to the mitochondria
using immunogold labeled TDP-43 transmission electron microscopy (TEM) and mitochondrial isolation
methods There was no increase in full-length TDP-43 localized to the mitochondria in APP/PS1 mice compared
to wild-type (littermates); however, using C- and N-terminal-specific TDP-43 antibodies, the N-terminal (27 kDa,
N27) and C-terminal (30 kDa, C30) fragments of TDP-43 are greatly enriched in mitochondrial fractions. In
addition, when the mitochondrial peptidase (PMPCA) is overexpressed there is an increase in the N-terminal
fragment (N27). These results suggest that TDP-43 processing may contribute to metabolism and mitochondrial
function.
1. Introduction
The heterogeneous nuclear ribonucleoprotein (hnRNP) TDP-43,
participates in exon skipping, RNA stability, RNA transport, splicing,
translation, microRNA processing, cellular stress, and localizes to the
mitochondria [6,7,40,45,48]. TDP-43 is the major pathological protein
in frontotemporal lobar degeneration (FTLD) and amyotrophic lateral
sclerosis/motor neuron disease (ALS/MND) [2,27]. In addition, TDP-43
proteinopathy may be present as a comorbidity in approximately
19–57% of cases of sporadic AD [1,3,18,22,27,41]. The pathology of
TDP-43 consists of ubiquitination, hyperphosphorylation and proteo-
lytic cleavage of TDP-43, into 35 kDa and 25 kDa insoluble aggregates,
the major component of the inclusion bodies [2,31]. Full-length and C-
terminal fragment (25 kDa) of TDP-43 overexpression in NSC-34 cells
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has been shown to increase mitophagy, but little is known about the
mechanisms by which overexpression of TDP-43 induces mitophagy
[19,28,50]. Distinct changes in mitochondrial dynamics, including
mitochondrial aggregation, have been reported in some mouse models
of TDP-43 [37,39,47,54,55]. Mitochondrial dynamics are orchestrated
by regulators of fusion, including mitofusin 1 and 2 (MFN1 and MFN2),
along with dynamin-related protein 1 (DRP1), a regulator of fission
[8,13]. Specifically, one study showed that MFN2 overexpression res-
cued TDP-43 induced mitochondrial dysfunction [47], while other re-
search found that overexpression of MFN2 induced mitochondrial
dysfunction and clustering [20,54], with the latter study supporting a
model of neurodegeneration involving TDP-43 overexpression [20,54].
Additionally, a recent report showed that full-length TDP-43 localizes
to the mitochondrial fraction during stress-induced conditions in au-
tosomal dominant ALS. Interestingly, by reducing localization of TDP-
43 to the mitochondria, ALS transgenic mice show improved motor
function [46,48]. However, another recent report found that ALS mu-
tant TDP-43 did not impair mitochondrial bioenergetics [23].
Misregulation of mitochondrial dynamics contributes to mitochon-
drial dysfunction in Alzheimer’s disease (AD) and other
Fig. 1. TDP-43 expression alters PHB2 expression and in-
duces LC3-II. A) Immunoprecipitation of TDP-43 and im-
munoblot (IB) with anti-PHB2. mIgG indicates mouse IgG
control, rIgG indicates rabbit IgG control. B)
Immunoprecipitation of PHB2 and TDP-43 and immunoblot for
TDP-43. C) Western blot for TDP-43, PHB2, LC3B, COXIV and
Tubulin from lysed HEK293T cells transfected with siNC (ne-
gative control), siTDP-43, vector (PLX), or v5 tagged TDP-43
(TDP-43v5) and treated with either 10 μM CCCP (indicated
by+ above lane) or DMSO as a control (indicated by −) for
12 h. D-E) Quantitation of TDP-43/Tubulin from Western blot
above. F-G) Quantitation of PHB2/Tubulin from Western blot
above. H-I) Quantitation of LC3-II/tubulin from Western blot
above. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001. ANOVA with Tukey correction for Type I
error. Error bars represent standard deviation.
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neurodegenerative diseases [4,5,33,35]. The APP/PS1 transgenic
mouse model co-expresses familial AD Swedish mutations
(APPK595N,M596L) and mutant human presenilin 1 (PSEN1-ΔE9) [21],
recapitulates features of pathologic AD, and displays alterations in
metabolism that affect respiratory function, mitochondrial biogenesis,
and mitophagy [32,49]. With the different findings related to TDP-43,
mitochondrial dynamics, and stress, and since we previously described
an increase in cytoplasmic accumulation of endogenous TDP-43 in
APP/PS1 mice, we wanted to determine if TDP-43 under stress would
accumulate within the mitochondria [14]. Using several methods in-
cluding proteomics, immunoprecipitation, immunogold TEM, mi-
tochondrial fractionation, immunoblotting, and bioenergetics we stu-
died the role that TDP-43 plays in mitophagy and mitochondrial
dynamics. Our data may provide new insights into the role TDP-43
plays in mitochondrial dynamics.
2. Materials and methods
For complete methods describing mice, transmission electron mi-
croscopy, mitochondrial isolation, cell culture, transfections, siRNA,
CCCP treatment, immunofluorescent staining, immunoprecipitation,
Western blots, proteomics, bioenergetics analysis (Seahorse, Agilent),
and statistical analysis please see supplementary material.
3. Results
3.1. TDP-43 interacts with prohibitin 2 and increases mitophagy
Initially we investigated if a change in TDP-43 expression altered
mitochondrial bioenergetics. In HEK293T cells overexpressing and
knocking down TDP-43, we saw no change in normalized oxygen
consumption rate (OCR) and extracellular acidification rate (ECAR)
(Seahorse, Agilent) (Fig. S1). This is supported from previous work that
examined these changes in patient-derived mutant TDP-43 fibroblasts
[23]. Interestingly, it has been recently reported that primary fibro-
blasts derived from sporadic ALS patients show no TDP-43 pathology,
which may limit their use with respect to mitochondrial dysfunction
[11].
To identify TDP-43 interacting partners, immunoprecipitated TDP-
43 from cortex lysate in wild-type mice was evaluated through pro-
teomic analysis. Proteomic analysis revealed several other mitochon-
drial proteins that interact with TDP-43 as well as non-mitochondrial
proteins (Fig. S2) [14,26,43]. The subcellular locations, functions, and
known interactions for these mitochondrial proteins are represented by
the interactive map (Fig. S3). Five out of eight of the mitochondrial
TDP-43 interacting proteins had known interactions with each other,
including Prohibitin 2 (PHB2) and voltage-gated dependent anion
channel 1 (VDAC1). We first validated these interactions with TDP-43
using co-immunoprecipitation (Fig. 1A and B and Fig. S4). We chose to
focus on the interaction between TDP-43 and PHB2 since PHB2 is a
critical receptor for mitophagy [52]. Moreover, loss of PHB2 causes
mitochondrial instability and leads to tau hyperphosphorylation and
neurodegeneration [29].
We investigated whether TDP-43 expression regulates PHB2 protein
expression levels. When TDP-43 was knocked down (siTDP-43) in
HEK293T cells, PHB2 protein expression was not significantly altered
under normal conditions (Fig. 1C, D and F). However, upon treatment
with the mitochondria uncoupler and autophagy inducer, CCCP (10 μM
for 12 h), there was a 20% significant reduction in PHB2 (p < 0.01)
when TDP-43 was knocked down (p= .0006) (Fig. 1C,F). When TDP-43
(v5-tagged) is overexpressed in cells treated with CCCP, (Fig. 1C,E)
PHB2 levels were higher independent of CCCP treatment (Fig. 1C,G).
We did not see a significant change in PHB2 levels upon CCCP treat-
ment alone without TDP-43 overexpression (Fig. 1C,G).
PHB2 has been shown to be a crucial receptor for Parkin-mediated
mitophagy and interacts with LC3-II [25]. We observed an increase in
Parkin-positive punctate staining in cells treated with CCCP, which was
enhanced with TDP-43 overexpression and reduced when TDP-43 was
knocked down (Fig. S5). Overall, CCCP treatment led to an increase in
LC3-II and a decrease in COXIV (Fig. 1C,H–J). However, there was
significantly less (12%, p= .024) LC3-II when TDP-43 expression was
reduced (Fig. 1C,H). This may indicate that TDP-43 expression is re-
quired for full activation of CCCP-induced mitophagy. Interestingly,
TDP-43 overexpression alone significantly increased LC3-II (75%,
p= .0012) expression to the same level induced by CCCP treatment
(Fig. 3C,I). TDP-43 overexpression in cells treated with CCCP led to a
marginal increase in LC3 compared to the vector control (Fig. 1C,I).
Additionally, we see TDP-43 labeled mitochondria near lysosomes in
mouse hippocampal sections using TEM (Fig. S6). We observed dis-
organized mitochondrial membranes in close proximity to TDP-43-la-
beled lysosomes indicating a possible link between TDP-43 and mi-
tochondrial organization and degradation (Fig. S6).
3.2. Selective expression of TDP-43 in the hippocampus and cortex leads to
an age-dependent change in fusion and fission
Since TDP-43 has been shown to localize to mitochondria, we were
interested in whether TDP-43 overexpression affects mitochondrial fu-
sion/fission dynamics. Mitofusin2 (MFN2) is a critical regulator of
mitochondrial fusion. Knocking down TDP-43 in HEK293T cells led to a
37 ± 0.016% (p= .0006) reduction in MFN2 protein whereas TDP-43
overexpression marginally increased MFN2 levels (Fig. S7A–C). We
determined that TDP-43 interacts in complex with MFN2 by im-
munoprecipitation using cortical human brain tissue (Fig. S7D).
Mitochondrial morphology was altered in 9-month old APP/PS1 mice
expressing hTDP-43 in the cortex and hippocampus (Camk2a-tTA/tetO-
hTDP-43/APP/PS1) that correlates with the increase in MFN2 expres-
sion (Fig. 1A,E–G). Furthermore, we utilized mice with selective ex-
pression of human TDP-43 in cortex and hippocampus (Camk2a-tTA/
tetO-hTDP-43) and examined changes in MFN2 as well as dynamin-
related protein 1 (DRP1), which is reported to play a key role in fission,
at 4 months and 9 months of age. The dynamin family GTPase fusion
protein, optic atrophy 1 (OPA1) showed no change in expression
(Fig. 2B, E ) [10]. In the cortex and hippocampus of 4-month old mice,
there was no difference in MFN2 expression but there was a two-fold
increase in MFN2 in Camk2a/hTDP-43 age (1.94 ± 0.24, p= .012)
and CAmk2a/hTDP-43/APP/PS1 (1.82 ± 0.22 p= .025) mice at 9
months of (Fig. 2B–C, E and F). There was a 3.24-fold ± 0.55,
(p= .018) increase in phospho-DRP1(Ser637) implicated in fission in-
hibition in Camk2a/hTDP-43 mice compared to wild-type littermates in
4-month-old mice. Though there was an increase trend in expression of
pDRP1(Ser637) in APP/PS1 and Camk2a/hTDP-43 it was not sig-
nificantly increased at 9 months of age (WT to APP/PS1 (p= .44); WT
to Camk2a/hTDP-43 (p= .10) (Fig. 2B,D,E,G)[8,13]. Taken together
with the morphological changes in mitochondria observed these results
indicate that TDP-43 may play a role in age-dependent changes in
mitochondrial dynamics through regulation of MFN2.
3.3. Ultrastructure of endogenous TDP-43 proximal to mitochondria
TDP-43 has been shown to mislocalize from the nucleus to the cy-
toplasm in response to beta-amyloid toxicity. Likewise, in both FTLD
and ALS abnormally aggregated TDP-43, in the form of inclusion
bodies, is found in the cytoplasm. Interestingly, abnormal TDP-43 in-
clusion bodies are also frequently seen in late-onset AD and other age-
related neurodegenerative diseases [17]. Recently, it was shown that
TDP-43 with ALS-associated mutations localized to mitochondria
whereas very little wild-type TDP-43 was detected in mitochondria
[47]. In APP/PS1 mice there is an increase in cytoplasmic endogenous
TDP-43 compared to wild-type mice [14]. Immunogold TEM revealed
both a nuclear and cytoplasmic distribution of endogenous TDP-43 in 8-
month old wild-type and APP/PS1 mice (Fig. S8). TDP-43 distribution
S.A. Davis et al. Neuroscience Letters 678 (2018) 8–15
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throughout hippocampal cells was similar between APP/PS1 and wild-
type mice (Fig. S8). TDP-43 was also found in close proximity to mi-
tochondria to a similar degree in both the APP/PS1 and wild-type mice
(Fig. 3A and B, Fig. S8), which may indicate that TDP-43 does no play a
role in the mitochondrial dysfunction seen in APP/PS1 mice. In the
APP/PS1 mice, there appeared to be no distinct aggregation of TDP-43
(Fig. S8). There were clusters of TDP-43 speckles in the cytoplasm that
may be indicative of sites of active translation or stress granules, similar
to the ultrastructure of TIA1, an RNA binding protein that promotes
stress granule formation and has been shown previously to localize to
TDP-43 (Fig. S8) [15]. This is similar to what has been observed in
sporadic ALS [30,34]. With TDP-43 localized to mitochondria and re-
cent work showing TDP-43 present in the mitochondrial fraction, we
next wanted to determine if TDP-43 increased in the mitochondrial
fraction in APP/PS1 mice [46,48].
3.4. Mitochondrial isolation reveals N-terminal and C-terminal TDP-43
fragments
In order to examine if there was an increase in mitochondrial TDP-
43, we used wild-type and APP/PS1 mouse cortical and hippocampal
tissue and performed Percoll density gradient fractionation to isolate
mitochondria [38]. Furthermore, we utilized two different TDP-43
antibodies to specifically detect N-terminal and C-terminal TDP-43
fragments [14]. We detected distinctly different TDP-43 fragment sizes
enriched in mitochondria fractions: a 27 kDa N-terminal fragment
Fig. 2. Selective expression of TDP-43 induces an age-dependent increase in Mitofusin-2. A) Transmission electron microscopy of hippocampal neurons in 9-
month old APP/PS1 and Camk2a/hTDP-43/APP/PS1 at 20,000X. B) Western blot for MFN2, OPA1, phospho-DRP1 (pDRP1) (Ser637), COXIV and Tubulin from
lysate of cortex extracted from 4-month-old non-transgenic (WT), APP/PS1, Camk2a/hTDP-43, and Camk2a/hTDP-43/APP/PS1 mice. C & D) Quantitation of 4-
month-old MFN2 and pDRP1 expression over Tubulin normalized to wild-type. E) Western blot for MFN2, OPA1, pDRP1(Ser637), and Tubulin from lysate of cortex
extracted from 9-month-old non-transgenic (WT), APP/PS1, and Camk2a/hTDP-43 mice. F & G) Quantitation of 9-month-old MFN2 and pDRP1 expression over
Tubulin normalized to wild-type.
S.A. Davis et al. Neuroscience Letters 678 (2018) 8–15
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(N27) and a 30 kDa C-terminal fragment (C30) (Fig. 3C). Although we
expected to see an increase in full-length TDP-43 in APP/PS1 mice, we
detected very little full-length TDP-43, which was not expressed sig-
nificantly more highly than non-transgenic mice (Fig. 3C and D).
However, there was a marginal increase in N-terminal TDP-43 (27 kDa)
(not significant) and a significant decrease in C-terminal TDP-43
(30 kDa) (WT 1.00 ± 0.110, APP/PS1 0.552 ± 0.116, p= .049)
(Fig. 3C, E and F). There was also a significant increase in the pre-
viously characterized 35 kDa and 25 kDa species in the total cell lysates
of APP/PS1 mice compared to wild-type, which were not found en-
riched in mitochondria (Fig. 3C, F and G). In total cell lysates, the N-
terminal TDP-43 antibody differentially detected expression of the
35 kDa TDP-43 whereas the C-terminal antibody detected 25 kDa TDP-
43, which are both significantly increased in APP/PS1 mice (Fig. 3C, G
and H). Although histone H3 was used as a marker for possible nuclear
protein contamination in mitochondria fractions, we noted a significant
decrease in histone H3 expression in APP/PS1 (0.457 ± 0.0304,
p= .006) compared to wild-type (1.00 ± 0.0962), which may indicate
a loss of soluble histone expression that needs further investigation
(Fig. 3C, I).
Due to the presence of the 27 kDa and 30 kDa TDP-43 fragments in
the mitochondrial fractions, we hypothesized that TDP-43 was pro-
cessed by mitochondrial peptidases in order to facilitate entry into
mitochondria. We overexpressed several mitochondrial peptidases and
screened for 27 kDa and 30 kDa TDP-43 by Western blotting. We chose
to focus on mitochondrial processing peptidase (MPP), presenilin-as-
sociated rhomboid-like protease (PARL), and ATPase family gene 3-like
2 (AFG3L2) because they were shown to affect degradation of phos-
phatase and tensin homologue-induced kinase 1 (PINK1), which re-
cruits Parkin to mitochondrial membranes during Parkin-mediated
Fig. 3. Mitochondrial fraction enhanced TDP-43 N- and C- terminal fragments. Transmission electron micrograph of immunogold labeled TDP-43 in the
hippocampus of 8-month-old A) wild-type and B) APP/PS1 mice. TDP-43 localizes around the mitochondria in wild-type and APP/PS1 mice; 19,500X (left) and
53,000X (right) magnification. C) Mitochondrial fraction (Percoll gradient) from the cortex/hippocampus of 9-month-old wild-type and APP/PS1 mice, im-
munoblotted for TDP-43 N-terminal (N-t), C-terminal (C-t), tubulin, COXIV, Histone H3, and APP (6E10) D) Quantification of mitochondrial full-length TDP-43
normalized to COXIV. E) Quantification of N-terminal TDP-43 (27 kDa) normalized to COXIV in mitochondrial fractions (band indicated by N27 in C). F)
Quantification of C-terminal TDP-43 (30 kDa) normalized to COXIV in mitochondrial fractions (band indicated by C30 in C). G) Quantification of 35 kDa TDP-43 (N-
terminal) from whole cell lysate normalized to Tubulin. H) Quantification of 25 kDa TDP-43 (C-terminal) from whole cell lysate normalized to Tubulin. I)
Quantification of histone H3 normalized to Tubulin from whole cell lysates. T, total lysate; M, mitochondrial fraction; *p < 0.05, **p < 0.01. Unpaired t-test, two-
tailed. Error bars represent standard deviation. J) Domain structure of TDP-43 displaying antibody epitopes for TDP-43 N-terminal (1–30) and C-terminal
(401–414) and the various forms of TDP-43 detected by each from cortex/hippocampus mitochondrial fractions and total lysates.
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mitophagy [16]. There was no increase in TDP-43 processing of the C30
fragment however there was significant increase of 2.37 ± 0.11
(p= .004) of the N27 fragment in total lysate as a result of over-
expression of peptidase mitochondrial processing alpha subunit
(PMPCA) (Fig. S9). This mechanism of TDP-43 processing by PMPCA
needs further investigation.
4. Discussion
Mitochondria are involved in multiple processes in the cell in-
cluding: oxidative phosphorylation to produce ATP, lipid metabolism,
calcium homoeostasis, apoptosis, and other functions [12,53]. With the
high-energy demand of neurons mitochondria are vital for synaptic
homeostasis [42]. Mitochondrial dysfunction is evident in age-related
neurodegenerative diseases including, but not limited to, Parkinson
disease, ALS, AD, and Huntington disease [4,5,33,35]. Full-length TDP-
43 localizes to the mitochondria during stress in familial ALS and both
wild-type and mutant TDP-43 bind to mitochondria-transcribed mRNAs
for mitochondria-encoded NADH:ubiquinone oxidoreductase core sub-
unit 3 (ND3) and subunit 6 (ND6) which interfere with their expression
causing complex I disassembly [48]. However, one report described low
levels of TDP-43 associated with the mitochondria and no change in
mitochondrial bioenergetics in ALS patient-derived fibroblasts and an
ALS mouse model [23]. It has been recently shown that no TDP-43
pathology was observed in primary fibroblasts derived from sporadic
ALS patients [11]. Pathogenic mechanism in ALS in part show increases
in oxidative stress and mitochondrial dysfunction (reviewed in [9]).
With no phosphorylated TDP-43 pathology present in patient derived
fibroblasts and only ubiquitin pathology seen in the TARDBP A315T
mouse model used for both these studies could limit recapitulation of
the mitochondrial dysfunction observed in ALS patients [11,51].
A proteomic screen of TDP-43 interacting proteins identified the
recently discovered mitophagy receptor PHB2 as interacting with TDP-
43 [52]. We hypothesize that TDP-43, through its interaction with
PHB2, may be involved in tethering mitochondria for degradation.
When TDP-43 is knocked down, less activation of CCCP-induced mi-
tophagy occurs. The complex interaction between TDP-43 and PHB2
may also be mediated through MFN2 and/or VDAC1 that was also
pulled down with TDP-43. It has been previously reported that muscle-
specific Mfn2 knockout mice reduces mitophagy and alters metabolic
homeostasis in an age-dependent manner [36]. A recent study in Dro-
sophila melanogaster showed that increasing mitofusin/marf amelio-
rated neurodegeneration in flies overexpressing human TDP-43 [24]. In
mice overexpressing TDP-43, mitochondria aggregation was associated
with an increase in fission proteins [54,55]. Through selective expres-
sion of TDP-43 in the hippocampus and cortex at 4 months of age there
is an increase in pDRP1(Ser637) shown to be inhibitory of fission and
an age-dependent increase in the fusion protein, MFN2, which also
interacts in complex with TDP-43. This may relate to the age-dependent
changes associated with fusion/fission dynamics observed in our model
of TDP-43 overexpression. We further show in human cells that
knocking down TDP-43 also decrease MFN2, which suggests that TDP-
43 may have a pivotal role in mitochondrial dynamics.
The pathological increase in TDP-43 in the mitochondria may
contribute to the changes associated with ALS [48]. In APP/PS1 mice
we observed no increase in full-length TDP-43 in the mitochondria
fraction; however, N- and C- fragments of TDP-43 were enhanced in the
mitochondrial fraction. There was also a marginal decrease in the TDP-
43 C30 fragment in APP/PS1 mitochondria, which may indicate that a
balance between the N- and C-terminal fragments are required for
normal homeostasis of TDP-43 in the mitochondria. When the mi-
tochondrial peptidase PMPCA is overexpressed there was an increase in
the N27 fragment. It has been previously reported that PMPCA interacts
in complex with ubiquinol-cytochrome c reductase core protein 1
(UQCRC1) [44]. Interestingly, UQCRC1 was one of the mitochondrial
proteins that co-immunoprecipitated with TDP-43. Although the
relationship between PMPCA and TDP-43 processing and the role of
TDP-43 plays in mitophagy needs further investigation, these data
collectively help to further characterize the relationship between TDP-
43 and the mitochondria.
5. Conclusion
Our findings do not show an increase in full-length TDP-43 localized
to the mitochondrial fraction in APP/PS1 mice. Interestingly, the TDP-
43C- and N-terminal fragments are enriched in the mitochondrial
fraction and when the mitochondrial peptidase PMPCA is over-
expressed we observe an increase in the N27 fragment. The role of these
fragments needs further study. Investigating proteins that interact with
TDP-43 may elucidate the normal function and delicate balance TDP-43
plays in neurodegeneration. These observations expand our under-
standing of mitophagy and fusion/fission dynamics and provide novel
insights into the possible role TDP-43 plays in mitochondrial dysfunc-
tion.
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